Showing 2151-2160 of 7669 results for "".
- EADV News: Almirall’s Ilumetri Improves Well-being of Pso Patients and Their Familieshttps://practicaldermatology.com/news/eadv-news-almiralls-ilumetri-improves-well-being-of-pso-patients-and-their-families/2462056/Ilumetri (tildrakizumab) significantly improves the well-being of psoriasis patients and their relatives, according to new data presented at the European Association of Dermatology and Venereology Congress 2023. Interim data from the POSITIVE study showed that tildrakizumab significantly improved …
- InMode: Employees in Isreal Are Safehttps://practicaldermatology.com/news/inmode-employees-in-isreal-are-safe/2462053/InMode Ltd. has affirmed the safety of the employees at the Company's Yokneam, Israel headquarters and does not anticipate any interruption in productionas a result of the Israel-Hamas War, "InMode is committed to supporting all customers, distributors, employees, and salespeople worldwide. We pri…
- One to Watch: AnaptysBio Inc.’s Imsidolimab (IL-36R) Shows Promise in GPPhttps://practicaldermatology.com/news/one-to-watch-imsidolimab-il-36r-shows-promise-in-gpp/2462052/AnaptysBio, Inc.’s Imsidolimab (IL-36R) performed well in in Generalized Pustular Psoriasis (GPP), according to topline results from the Phase 3 GEMINI-1 trial. Imsidolimab is an IgG4 antibody that inhibits the function of the interleukin-36 receptor (IL-36R), a signaling pathway within the immune…
- Study: Stigmatization Widespread Among Europeans With Skin Diseaseshttps://practicaldermatology.com/news/stigmatization-widespread-among-europeans-with-skin-diseases/2462051/Almost all European people who are affected by skin diseases face embarrassment, with the psychological burden compounding the physical impact of living with the condition, according to a new report, The Burden of Skin Disease in Europe, which published today in the Journal of the European Academy …
- FDA Approves Novartis Cosentyx as First IV Formulation IL-17A Antagonist for PsAhttps://practicaldermatology.com/news/fda-approves-novartis-cosentyx-as-first-iv-formulation-il-17a-antagonist-for-psa/2462048/The US Food and Drug Administration (FDA) has approved an intravenous (IV) formulation of Novartis’ Cosentyx (secukinumab) for the treatment of adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). Cosentyx is the only treatment…
- CDC Awards Grant to National Eczema Associationhttps://practicaldermatology.com/news/cdc-awards-grant-to-national-eczema-association/2462047/The National Eczema Association (NEA) was recently awarded a grant from the Centers for Disease Control and Prevention (CDC): The 4-year Chronic Disease Awareness and Engagement grant will support NEA's project titled "Atopic Dermatitis is More Than a Skin Disease: Raising Awareness and Improving C…
- Crown Therapeutics Rolls Out PanOxyl Clarifying Exfoliant, PanOxyl Adapalene 0.1% Gelhttps://practicaldermatology.com/news/crown-therapeutics-rolls-out-panoxyl-clarifying-exfoliant-panoxyl-adapalene-01-gel/2462039/Crown Therapeutics is launching two new PanOxyl products: PanOxyl Clarifying Exfoliant with 2% Salicylic Acid and PanOxyl Adapalene 0.1% Gel. PanOxyl Clarifying Exfoliant features a pH-balanced, alcohol-free formula that can be used daily without any harsh effects. PanOxyl Clarifying Exfoliant is …
- Cabaletta Bio Receives FDA Clearance of IND Application for Treatment of Systemic Sclerosis with CABA-201https://practicaldermatology.com/news/cabaletta-bio-receives-fda-clearance-of-ind-application-for-treatment-of-systemic-sclerosis-with-caba-201/2462036/The U.S. Food and Drug Administration (FDA) is allowing Cabaletta Bio, Inc.’s third Investigational New Drug (IND) application for CABA-201 to proceed. for a Phase 1/2 study in patients with systemic sclerosis (SSc). CABA-201 is a 4-1BB-containing fully human CD19-CAR T cell investigational thera…
- Industry Vet Brent Hauser Named President, International at Cuterahttps://practicaldermatology.com/news/industry-vet-brent-hauser-named-president-international-at-cutera/2462034/Brent Hauser is the new President, International, at Cutera, Inc. Mr. Hauser will report directly to Taylor Harris, Cutera’s Chief Executive Officer, and will be responsible for commercial performance in existing international markets, expansion into new geographies, and the international launch o…
- Can Phages Help Treat AD?https://practicaldermatology.com/news/can-phages-help-treat-adp/2462033/Bacteriophages or bacteria eaters may be a new therapy option for people with atopic dermatitis (AD), according to a study in Science Advances. A MedUni Vienna team has investigated the interaction of phages and bacteria in the skin for the first time. It has long been known that the progression o…